Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | dihydrolipoyl dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Schistosoma mansoni | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0054 | 0.3888 | 0.5 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0054 | 0.3888 | 0.5 |
Plasmodium falciparum | thioredoxin reductase | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma brucei | trypanothione reductase | 0.0095 | 1 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0054 | 0.3888 | 0.5 |
Plasmodium falciparum | thioredoxin reductase | 0.0095 | 1 | 1 |
Trypanosoma brucei | dihydrolipoyl dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0054 | 0.3888 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0054 | 0.3888 | 0.5 |
Trypanosoma cruzi | dihydrolipoyl dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Plasmodium vivax | dihydrolipoyl dehydrogenase, apicoplast, putative | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Schistosoma mansoni | histone deacetylase hda2 | 0.0047 | 0.2735 | 0.1128 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0095 | 1 | 1 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0054 | 0.3888 | 0.5 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0095 | 1 | 1 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0054 | 0.3888 | 0.5 |
Echinococcus granulosus | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0054 | 0.3888 | 0.2603 |
Treponema pallidum | NADH oxidase | 0.0054 | 0.3888 | 0.5 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0095 | 1 | 1 |
Brugia malayi | Histone deacetylase family protein | 0.004 | 0.1812 | 0.009 |
Plasmodium falciparum | glutathione reductase | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0095 | 1 | 1 |
Loa Loa (eye worm) | histone deacetylase | 0.004 | 0.1812 | 0.1812 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0054 | 0.3888 | 0.5 |
Toxoplasma gondii | pyruvate dehydrogenase complex subunit PDH-E3II | 0.0054 | 0.3888 | 0.2536 |
Loa Loa (eye worm) | glutathione reductase | 0.0095 | 1 | 1 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.5 |
Echinococcus multilocularis | histone deacetylase 6 | 0.0047 | 0.2735 | 0.1128 |
Leishmania major | acetoin dehydrogenase e3 component-like protein | 0.0054 | 0.3888 | 0.2536 |
Plasmodium vivax | glutathione reductase, putative | 0.0095 | 1 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0095 | 1 | 1 |
Brugia malayi | Histone deacetylase family protein | 0.004 | 0.1812 | 0.009 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0095 | 1 | 1 |
Echinococcus multilocularis | dihydrolipoamide dehydrogenase | 0.0054 | 0.3888 | 0.2536 |
Toxoplasma gondii | thioredoxin reductase | 0.0095 | 1 | 1 |
Toxoplasma gondii | NADPH-glutathione reductase | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Plasmodium vivax | dihydrolipoyl dehydrogenase, mitochondrial, putative | 0.0054 | 0.3888 | 0.2536 |
Leishmania major | trypanothione reductase | 0.0095 | 1 | 1 |
Loa Loa (eye worm) | histone deacetylase 7A | 0.004 | 0.1812 | 0.1812 |
Trypanosoma brucei | dihydrolipoamide dehydrogenase, point mutation | 0.0054 | 0.3888 | 0.2536 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0054 | 0.3888 | 0.2536 |
Plasmodium falciparum | dihydrolipoyl dehydrogenase, apicoplast | 0.0054 | 0.3888 | 0.2536 |
Loa Loa (eye worm) | hypothetical protein | 0.0034 | 0.0923 | 0.0923 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Echinococcus granulosus | histone deacetylase 6 | 0.0047 | 0.2735 | 0.1128 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0054 | 0.3888 | 0.5 |
Brugia malayi | Thioredoxin reductase | 0.0095 | 1 | 1 |
Trypanosoma cruzi | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Leishmania major | dihydrolipoamide dehydrogenase, putative | 0.0054 | 0.3888 | 0.2536 |
Leishmania major | 2-oxoglutarate dehydrogenase, e3 component, lipoamidedehydrogenase-like protein | 0.0054 | 0.3888 | 0.2536 |
Plasmodium falciparum | glutathione reductase | 0.0095 | 1 | 1 |
Plasmodium falciparum | dihydrolipoyl dehydrogenase, mitochondrial | 0.0054 | 0.3888 | 0.2536 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 70 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.0015+0.06 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 73 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.003+0.015 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 74 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.0015+0.005 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 76 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.003+0.06 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 79 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.006+0.06 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 85 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.006+0.015 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 91 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.006+0.005 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 91 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.003+0.005 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 94 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.012+0.015 microM | ChEMBL. | 1901911 |
Inhibition (functional) | = 96 % | Anti-HIV-1 activity against syncytial plaque formation at a conc. of 0.012+0.005 microM | ChEMBL. | 1901911 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.